Teleflex Completes Enrollment in Percutaneous Coronary Intervention Study
19 Julho 2023 - 7:30AM
Teleflex Incorporated (NYSE: TFX), a leading global provider of
medical technologies, today announced the completion of patient
enrollment in the prospective multicenter RingerTM PTCA study.
RingerTM PTCA is one of two clinical studies evaluating the
performance of the novel RingerTM Perfusion Balloon Catheter. The
RingerTM PTCA study enrolled patients at seven leading complex PCI
centers in the US and Canada. Led by Principal Investigator
Kathleen Kearney M.D., University of Washington, the study employed
the RingerTM Device in selected coronary intervention patients who
could benefit from continued perfusion during coronary balloon
inflations.
“Completing enrollment is a significant milestone in the
clinical validation and regulatory pathway to release the RingerTM
Perfusion Balloon Catheter to treat patients,” said Teleflex
Medical Director, Dr. Christopher Buller.
Running in parallel to the RingerTM PTCA study is a 30-patient
prospective study evaluating the safety and utility of RingerTM for
emergently managing coronary perforations complicating PCI
procedures. Coronary perforations, though infrequent, can be
life-threatening events that demand rapid treatment. Currently
there are no commercially available devices designed to temporarily
control bleeding from coronary perforations pending definitive
treatment or to seal perforations without leaving behind a
permanent coronary implant.
“Availability of RingerTM is much anticipated by the
interventional cardiology community, and completion of enrollment
in RingerTM PTCA puts us a big step closer to that goal,” said
Kathleen Kearney M.D., University of Washington.
About Teleflex
IncorporatedTeleflex is a global provider of
medical technologies designed to improve the health and quality of
people’s lives. We apply purpose driven innovation – a relentless
pursuit of identifying unmet clinical needs – to benefit patients
and healthcare providers. Our portfolio is diverse, with solutions
in the fields of vascular access, interventional cardiology and
radiology, anesthesia, emergency medicine, surgical, urology and
respiratory care. Teleflex employees worldwide are united in the
understanding that what we do every day makes a difference. For
more information, please visit teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, LMA®, Pilling®,
QuikClot®, Rusch®, UroLift® and Weck® – trusted brands united by a
common sense of purpose.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which
may cause actual results or company actions to differ materially
from what is expressed or implied by these statements. These risks
and uncertainties are identified and described in more detail in
our filings with the Securities and Exchange Commission, including
our Annual Report on Form 10-K.
*Dr. Kearney is a paid consultant of Teleflex Incorporated.
CAUTION: RingerTM is an investigational device and is limited by
federal (or United States) law to investigational use.
CAUTION: Federal (USA) law restricts these devices for sale or
use by or on the order of a physician.
Teleflex, the Teleflex logo, Arrow, Deknatel, GuideLiner, LMA,
Pilling, QuikClot, Ringer, Rusch, UroLift, and Weck are trademarks
or registered trademarks of Teleflex Incorporated or its affiliates
in the U.S. and/or other countries. Refer to the Instructions
for Use for a complete listing of the indications,
contraindications, warnings, and precautions. Information in this
document is not a substitute for the product Instructions for
Use. Not all products may be available in all
countries. Please contact your local representative.
© 2023 Teleflex Incorporated. All rights reserved.
MC-009018.
Contacts:
For Teleflex Incorporated:Lawrence KeuschVice President,
Investor Relations and Strategy Development
investor.relations@teleflex.com610.948.2836
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Teleflex (NYSE:TFX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024